Trials / Not Yet Recruiting
Not Yet RecruitingNCT06438913
Tezepelumab Treatment in Korean Severe Asthma Patients
The Improvement of Cough Outcomes After Tezepelumab Treatment in Korean Severe Asthma Patients With Airway Hyperresponsiveness
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
There is no study that systematically evaluated the effect of Tezepelumab on cough, and based on this background, the present researchers aimed to evaluate the effect of Tezepelumab treatment in patients with severe asthma who complain of cough using the Leicester Cough Questionnaire, a cough-related quality of life measurement tool.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tezepelumab | Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation. |
Timeline
- Start date
- 2024-06-12
- Primary completion
- 2025-05-12
- Completion
- 2026-12-31
- First posted
- 2024-06-03
- Last updated
- 2024-06-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06438913. Inclusion in this directory is not an endorsement.